Title: Compound Selectivity and Target Residence Time of Kinase Inhibitors Studied with Surface Plasmon Resonance.
Journal: Journal of molecular biology20170217
Title: Synergistic induction of cell death in haematological malignancies by combined phosphoinositide-3-kinase and BET bromodomain inhibition.
Journal: British journal of haematology20150701
Title: Dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 synergizes with chloroquine to induce apoptosis in embryonal rhabdomyosarcoma.
Journal: Cancer letters20150428
Title: Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models.
Journal: Cancer letters20140201
Title: Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor α signalling and results in tamoxifen insensitive proliferation.
Journal: BMC cancer20140101
Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters20130801
Title: PI3Kδ inhibition augments the efficacy of rapamycin in suppressing proliferation of Epstein-Barr virus (EBV)+ B cell lymphomas.
Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons20130801
Title: Dual inhibitor of phosphoinositide 3-kinase/mammalian target of rapamycin NVP-BEZ235 effectively inhibits cisplatin-resistant urothelial cancer cell growth through autophagic flux.
Journal: Toxicology letters20130718
Title: Efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in a preclinical model of adrenocortical carcinoma.
Journal: Molecular and cellular endocrinology20121125
Title: NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy.
Journal: Expert opinion on investigational drugs20121101
Title: Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones.
Journal: Cancer letters20121001
Title: 3D tumour spheroids as a model to assess the suitability of [18F]FDG-PET as an early indicator of response to PI3K inhibition.
Journal: Nuclear medicine and biology20121001
Title: Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines.
Journal: Journal of molecular endocrinology20121001
Title: IL-22 induced cell proliferation is regulated by PI3K/Akt/mTOR signaling cascade.
Journal: Cytokine20121001
Title: Inhibition of phosphoinositide-3 kinase pathway down regulates ABCG2 function and sensitizes malignant pleural mesothelioma to chemotherapy.
Journal: Lung cancer (Amsterdam, Netherlands)20121001
Title: Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20121001
Title: Phosphatidylinositol 3-kinase/Akt signaling pathway activates the WNK-OSR1/SPAK-NCC phosphorylation cascade in hyperinsulinemic db/db mice.
Journal: Hypertension (Dallas, Tex. : 1979)20121001
Title: Dual PI3K/mTOR inhibitor NVP-BEZ235 suppresses hypoxia-inducible factor (HIF)-1α expression by blocking protein translation and increases cell death under hypoxia.
Journal: Cancer biology & therapy20120901
Title: Determination of NVP-BEZ235, a dual PI3K and mTOR inhibitor, in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography with fluorescence detection.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences20120715
Title: Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia.
Journal: Oncogene20120705
Title: The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells.
Journal: Leukemia research20120701
Title: Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification.
Journal: Molecular cancer therapeutics20120701
Title: mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma.
Journal: Science translational medicine20120620
Title: Predominance of mTORC1 over mTORC2 in the regulation of proliferation of ovarian cancer cells: therapeutic implications.
Journal: Molecular cancer therapeutics20120601
Title: Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines.
Journal: Cancer chemotherapy and pharmacology20120601
Title: Cotargeting signaling pathways driving survival and cell cycle circumvents resistance to Kit inhibitors in leukemia.
Journal: Blood20120503
Title: A selective inhibitor reveals PI3Kγ dependence of T(H)17 cell differentiation.
Journal: Nature chemical biology20120429
Title: The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition.
Journal: British journal of cancer20120410
Title: The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer.
Journal: Journal of cellular biochemistry20120301
Title: Effects of acutely inhibiting PI3K isoforms and mTOR on regulation of glucose metabolism in vivo.
Journal: The Biochemical journal20120215
Title: An animal model of MYC-driven medulloblastoma.
Journal: Cancer cell20120214
Title: Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells.
Journal: Cancer cell20120214
Title: The phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 is effective in inhibiting regrowth of tumour cells after cytotoxic therapy.
Journal: European journal of cancer (Oxford, England : 1990)20120201
Title: The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells.
Journal: Anticancer research20120201
Title: Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma.
Journal: Science translational medicine20120104
Title: Current development of the second generation of mTOR inhibitors as anticancer agents.
Journal: Chinese journal of cancer20120101
Title: The PI3-kinase/mTOR-targeting drug NVP-BEZ235 inhibits growth and IgE-dependent activation of human mast cells and basophils.
Journal: PloS one20120101
Title: The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses.
Journal: Neoplasia (New York, N.Y.)20120101
Title: Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells.
Journal: BMC cancer20120101
Title: NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity.
Journal: Radiation oncology (London, England)20120101
Title: Combination of phosphatidylinositol 3-kinases pathway inhibitor and photodynamic therapy in endothelial and tumor cells.
Journal: Photochemistry and photobiology20120101
Title: Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
Journal: PloS one20120101
Title: Modulators of sensitivity and resistance to inhibition of PI3K identified in a pharmacogenomic screen of the NCI-60 human tumor cell line collection.
Journal: PloS one20120101
Title: Growth inhibition by NVP-BEZ235, a dual PI3K/mTOR inhibitor, in hepatocellular carcinoma cell lines.
Journal: Oncology reports20111101
Title: Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474).
Journal: Journal of medicinal chemistry20111027
Title: Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20111015
Title: Augmentation of NVP-BEZ235's anticancer activity against human lung cancer cells by blockage of autophagy.
Journal: Cancer biology & therapy20110915
Title: The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells.
Journal: Breast cancer research and treatment20110901
Title: Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20110815
Title: Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.
Journal: Cancer research20110801
Title: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.
Journal: The Journal of clinical investigation20110701
Title: Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells.
Journal: Cancer biology & therapy20110601
Title: A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations.
Journal: Nature structural & molecular biology20110601
Title: The inhibition of MAPK potentiates the anti-angiogenic efficacy of mTOR inhibitors.
Journal: Biochemical and biophysical research communications20110422
Title: Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20110415
Title: The novel Raf inhibitor Raf265 decreases Bcl-2 levels and confers TRAIL-sensitivity to neuroendocrine tumour cells.
Journal: Endocrine-related cancer20110401
Title: Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo.
Journal: Oncogene20110317
Title: The dual PI3K/mTOR inhibitor BEZ235 is effective in lung cancer cell lines.
Journal: Anticancer research20110301
Title: The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo.
Journal: PloS one20110101
Title: Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib.
Journal: Molecular cancer20110101
Title: Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer.
Journal: Journal of translational medicine20110101
Title: The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer.
Journal: PloS one20110101
Title: A mechanism for synergy with combined mTOR and PI3 kinase inhibitors.
Journal: PloS one20110101
Title: S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer.
Journal: PloS one20110101
Title: Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20101215
Title: Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells.
Journal: Neuro-oncology20101201
Title: Combination therapy targeting both tumor-initiating and differentiated cell populations in prostate carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20101201
Title: Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20101115
Title: Akt and autophagy cooperate to promote survival of drug-resistant glioma.
Journal: Science signaling20101109
Title: Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells.
Journal: Stem cells (Dayton, Ohio)20101101
Title: Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia.
Journal: Cancer research20101015
Title: NVP-BEZ235, a dual pan class I PI3 kinase and mTOR inhibitor, promotes osteogenic differentiation in human mesenchymal stromal cells.
Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research20101001
Title: The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma.
Journal: Leukemia20101001
Title: Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease.
Journal: Cancer letters20100901
Title: The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20100715
Title: Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas.
Journal: Blood20100603
Title: Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39.
Journal: European journal of cancer (Oxford, England : 1990)20100401
Title: Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.
Journal: Science translational medicine20100127
Title: Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia.
Journal: Blood20100121
Title: NVP-BEZ235 as a new therapeutic option for sarcomas.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20100115
Title: Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations.
Journal: Cancer research20091001
Title: NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas.
Journal: Molecular cancer therapeutics20090801
Title: Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
Journal: Cancer research20090715
Title: Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer.
Journal: Cancer research20090515
Title: PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer.
Journal: Cancer research20090501
Title: Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts.
Journal: British journal of cancer20090421
Title: Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition.
Journal: Molecular cancer therapeutics20090401
Title: Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors.
Journal: Molecular cancer research : MCR20090401
Title: The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma.
Journal: Experimental cell research20090201
Title: Effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor, on DNA-dependent protein kinase.
Journal: Biological & pharmaceutical bulletin20090201
Title: Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis.
Journal: Molecular cancer20090101
Title: Controversies in breast cancer: the mammalian target of rapamycin as a target for breast cancer therapy.
Journal: Breast cancer research : BCR20090101
Title: Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.
Journal: Cancer research20081115
Title: Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.
Journal: Nature chemical biology20081101
Title: NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
Journal: Cancer research20081001
Title: Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging.
Journal: Cancer research20080815
Title: Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.
Journal: Molecular cancer therapeutics20080701
Title: Maira SM, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther, 2008, 7(7), 1851-1863.
Title: Roper J, et al. The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer. PLoS One, 2011, 6(9), e25132.
Title: Lee M, et al. Targeting PI3K/mTOR Signaling Displays Potent Antitumor Efficacy against Nonfunctioning Pituitary Adenomas. Clin Cancer Res. 2015 Jul 15;21(14):3204-15.
